Healthcare
Live Price
Offline$0.1349
+0.00% today
1Y Change
-32.60%
Window
Jun 23, 2025 โ Jun 15, 2026
Coverage: 253 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viva Biotech Holdings (VBIZF) is a Healthcare stock with a market cap of $3.11B and listed on OTC. The stock last traded around $0.13 and down 32.6% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -15.2%, EPS growth of +27.7%, a dividend yield of 0.0%. What stands out right now is revenue -15.2%, EPS +27.7%, free cash flow -51.7% with operating margin 11.2% and ROIC 2.4%. Valuation is more restrained than many high-expectation growth names at P/E 6.4 and price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VBIZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-15.2% vs +7.6% peer median
Operating Margin
Below sector median
+11.2% vs +19.4% peer median
P/E
Below sector median
6.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -15.2% and EPS is at +27.7%, with operating margin around 11.2%.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VBIZF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VBIZF Max Drawdown
-65.07%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for VBIZF and SPY.

Company Overview
Viva Biotech Holdings
Other OTC
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.